1h
Zacks.com on MSNBiotech Stock Roundup: BLUE Down on Update, News From GILD, TRDAIt was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...
Fast-moving stars in the Milky Way indicate there could be a supermassive black hole in the neighboring Large Magellanic ...
The latest announcement follows the recent US Food and Drug Administration (FDA) acceptance of the company’s new drug ...
Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...
The discussion ended with a bold call to action for businesses, healthcare providers, and policymakers: health equity must be a priority—not just ethically, but economically. As Burgess put it: “This ...
The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...
Missed KHOU 11+’s live Q&A on injectable PrEP? Watch on demand as experts discuss this HIV prevention breakthrough and answer ...
Bybit, the world's second-largest cryptocurrency exchange by trading volume, has completed a fresh round of audit on Feb. 23, 2025 conducted by leading cybersecurity firm Hacken. The independent third ...
In a remarkable convergence of ancient spiritual traditions and rare celestial phenomena, millions of seekers worldwide are ...
Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results